denosumab
amgen,daiichi sankyo
['denosumab']
denosumab freedom:9% incr spine, 4-5% incr hip bmd
ole: 10 yr a/w low risk of infxn, malig risk of aff 0.8/10k pt yr risk of onj 5.2/10k pt yr
bis --&gt; denos = greater gains in bmd vs
bis --&gt; bis
greatest gains of bis--&gt;deno where bis use &lt; 3yr
#acr22 #acrambassador
(pronounced VUH-neet sun-dhoo) Mother. She/Her/Hers. Rheumatologist. Program Director @lluhealth. Tweets are not medical advice. #ACRAmbassador @lluhphysicians